Posaconazole: Difference between revisions
From IDWiki
(→) |
No edit summary |
||
| Line 5: | Line 5: | ||
*For treatment, target trough >1 mg/L |
*For treatment, target trough >1 mg/L |
||
===Clinical Breakpoints=== |
|||
=== Epidemiologic Cutoff Values === |
|||
{| class="wikitable" |
{| class="wikitable" |
||
!Species |
! rowspan="2" |Species |
||
!ECV ( |
! rowspan="2" |ECV (μg/mL) |
||
! colspan="4" |Breakpoints (μg/mL) |
|||
! colspan="4" |Breakpoints (mm) |
|||
|- |
|- |
||
!S |
|||
|C. albicans |
|||
!SDD |
|||
!I |
|||
!R |
|||
!S |
|||
!SDD |
|||
!I |
|||
!R |
|||
|- |
|||
|[[Candida albicans]] |
|||
|0.06 |
|0.06 |
||
|≤0.06 |
|||
| |
|||
| |
|||
|≥0.12 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida dubliniensis]] |
|||
|C. glabrata |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida glabrata]] |
|||
|2 |
|2 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida guilliermondii]] |
|||
|C. parapsilosis |
|||
|0.5 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida kefyr]] |
|||
|0.25 |
|0.25 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida krusei]] |
|||
|C. tropicalis |
|||
|0.5 |
|||
| colspan="4" | |
|||
| colspan="4" | |
|||
|- |
|||
|[[Candida lusitaniae]] |
|||
|0.12 |
|0.12 |
||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida parapsilosis]] |
|||
|C. krusei |
|||
|0. |
|0.25 |
||
|≤0.06 |
|||
| |
|||
| |
|||
|≥0.12 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Candida tropicalis]] |
|||
|C. lusitaniae |
|||
|0.12 |
|0.12 |
||
|≤0.06 |
|||
| |
|||
| |
|||
|≥0.12 |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Cryptococcus neoformans]] |
|||
|C. guilliermondii |
|||
| |
| |
||
| colspan="8" rowspan="2" | |
|||
|- |
|- |
||
|[[Cryptococcus gattii]] |
|||
|C. kefyr |
|||
| |
|||
|0.25 |
|||
|} |
|} |
||
[[Category:Triazoles]] |
[[Category:Triazoles]] |
||
Revision as of 01:12, 20 January 2021
Therapeutic Drug Monitoring
- Measure trough 7 days after starting or adjusting dose, or adjusting interacting medications, or concerns of poor adherence or absorption
- For prophylaxis, target trough >0.7 mg/L, or random level 0.35 mg/L 48 h after starting therapy
- For treatment, target trough >1 mg/L
Clinical Breakpoints
| Species | ECV (μg/mL) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | SDD | I | R | S | SDD | I | R | ||
| Candida albicans | 0.06 | ≤0.06 | ≥0.12 | ||||||
| Candida dubliniensis | |||||||||
| Candida glabrata | 2 | ||||||||
| Candida guilliermondii | 0.5 | ||||||||
| Candida kefyr | 0.25 | ||||||||
| Candida krusei | 0.5 | ||||||||
| Candida lusitaniae | 0.12 | ||||||||
| Candida parapsilosis | 0.25 | ≤0.06 | ≥0.12 | ||||||
| Candida tropicalis | 0.12 | ≤0.06 | ≥0.12 | ||||||
| Cryptococcus neoformans | |||||||||
| Cryptococcus gattii | |||||||||
